BioVersys

BioVersys is a publicly listed Swiss pharmaceutical company focusing on R&D of small molecules acting on novel bacterial targets.

[BioVersys @Bioversys]

BioVersys and partners are pleased to share the publication of AlpE data in #NatureCommunications. Read more: https://t.co/CNtPc6ndRz
#GSK @univ_lille @PasteurLille #tuberculosis #antimicrobialresistance #globalhealth #biotech #drugdevelopment

[BioVersys @Bioversys]

#BioVersys announces that it has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health. https://t.co/CNtPc6ndRz
@HMHNewJersey @UMNews #HealthCareInnovation #Collaboration #AMR #Antibiotics #InfectiousDiseases

[BioVersys @Bioversys]

📡 BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start.
See: https://t.co/tdor3GSBWH
#SavingLivesInResistantTimes #HealthcareInnovation #AMR #biotech #antibiotics #CRAB

[BioVersys @Bioversys]

BioVersys Announces First Patient Dosed in Phase 2b Clinical Trial of AlpE in Pulmonary Tuberculosis. https://t.co/qTbyiBIdc7
@GSK @IHIEurope @UNITE4TB @EFPIA Deutsches Zentrum für Infektionsforschung (#DZIF), @LMU_Muenchen German Federal Ministry of Education and Research

[BioVersys @Bioversys]

📡 Meet BioVersys at the world renowned Gordon Research Conference, on New Antibacterial Discovery and Development on March 8-13, Lucca, Italy, to talk about our TB program in Phase 2.
https://t.co/NyQwz8lYP9
@EDCTP @GSK @taskapplied @IHIEurope @univ_lille @PasteurLille

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

Cutting-edge clinical development is in focus, starting with a new combination targeting A. baumannii, we'll move onto novel approaches addressing chlamydia infections and a brand-new antibiotic for treating UTIs.

🎥 Watch live now: https://t.co/EXNwZ6zIWc

#ACC2026 #AMR

[Global Antibiotic R&D Partnership (GARDP) @gardp_amr]

🚀🔬Day 2 kicks off with Session Five at #ACC2026

Clinical development and use of new agents takes centre stage as we dive into how emerging treatments move from trials to practice.

🎥 Join us live now:
https://t.co/vjCwiL1dvl

@Bioversys I @SSI_dk I @GSK

#AMR #ClinicalDevelopment

[Edison @Edison_Inv_Res]

BioVersys — Poised to unlock value in critical AMR

BioVersys is focused on developing novel drugs to address antimicrobial resistance (AMR)… @Bioversys $BIOV

📖 Full analysis: https://t.co/MGftIfJlOv

[BioVersys @Bioversys]

📡 BioVersys and partners’ Phase 2a tuberculosis trial results published in New England Journal of Medicine
@EDCTP @GSK @taskapplied @bEtoTB1 @NEJM
https://t.co/TBQiPMJlEf

[Venturelab @venturelab_ch]

From @ETH lab to @sixgroup Swiss Exchange: the @Bioversys antibiotic revolution 🧬 https://t.co/K36OGTRL0f

From an ETH Zürich spin-off to a publicly listed biotech tackling antibiotic resistance, BioVersys AG exemplifies how Swiss science can transform global health. With CHF 130 million raised, two WHO-priority drug candidates, and a CHF 213 million valuation on the SIX Swiss Exchange, the company is redefining the future of antibiotics. 💊

🗣️ As Founder & CEO Marc Gitzinger shares: “A world without access to working antibiotics would lead to losing the last 50 years of medical progress.”

Supported by @venturekick and Venture Leaders by Venturelab, BioVersys AG’s journey from a PhD project to clinical breakthroughs and global partnerships, shows the power of persistence, precision, and purpose in biotech innovation.

💡 Read how BioVersys is rebuilding the antibiotic pipeline and leading the charge against resistant bacteria.

Make sure to follow @venturekick to stay up to date on the latest breakthroughs, and discover the early-stage Swiss startups shaping the future of innovation!

#TOP100SSU #SwissStartups #Innovation #Entrepreneurship #StartupEcosystem

[BioVersys @Bioversys]

🚀More exciting progress and success in funding BioVersys programs - with BV100 Phase 2B to be conducted via Wellcome Funded Trial Network.
Link to full press release: https://t.co/5B4ibHLDkM

[BioVersys @Bioversys]

📡 @Bioversys and @SHIONOGI_JP, enter into Global Research Collaboration for broad-spectrum NTM clinical candidates. Read more here: https://t.co/BtNb9pTwPi

[BioVersys @Bioversys]

Click https://t.co/kFuD18KsiL for an informative KOL event; May 7, 2025, 8:30 AM ET / 2:30PM CEST. Featuring Professor David Paterson & Dr. Andrew Shorr, MD, discussing the unmet need & current treatment landscape for carbapenem resistant Acinetobacter baumannii pneumonia. #AMR

[BioVersys @Bioversys]

BioVersys announces joining the @AMRAccelerator EU-funded programme @RespiriNTM, access to up to €2 m in non-dilutive funding for our broad-spectrum NTM project. Read the full press release here: https://t.co/zFUoKAuQtY
#SavingLivesinResistantTimes #AMR #investment #Innovation

[BioVersys @Bioversys]

📡 Exciting times as BioVersys announces last patient, last visit in the Phase 2 clinical trial with BV100 showing positive first signs of efficacy for #VABP #CRAB. 🎯🌍 🏥
🚀 Read the full press release here: https://t.co/SCom3zT3fm
#SavingLivesinResistantTimes #AMR #Innovation

[BioVersys @Bioversys]

BioVersys announces strategic investment from GIBF2 and launch of BV100 clinical program in China.
· GIBF2 to invest US$ 6m in BioVersys
· BV100 Phase 1 study in China expected to start in 1H 2025
Press release: https://t.co/dubXVfOl6m
#AMR #investment #China #Innovation

[BioVersys @Bioversys]

#PassThePasteurAct

[BioVersys @Bioversys]

🤝 We are excited to collaborate with @lifearc1, @MedDiscCat and @cftrust to expedite BioVersys’ NTM program to address serious infections in people living with CF.  💊
See PR with details: https://t.co/SAfnKHKEzL

[BioVersys @Bioversys]

@CFAMRSyndicate @MedDiscCat @cftrust @lifearc1 Thank you for posting this @CFAMRSyndicate (Twitter issues prevented us do so until now) - we are delighted to have joined forces with you to address resistant infections in people living with CF!

[CF AMR Syndicate @CFAMRSyndicate]

🎉 We're excited to announce that @Bioversys has been awarded with non-dilutive funding via our CDP programme to advance the pipeline of preclinical assets for CF lung infections.

Read the press release https://t.co/VGmRFqlXwj

@MedDiscCat | @cftrust | @lifearc1